Opportunity
Alberta Purchasing #NOA 2024-0164
Award for Formulation and Characterization of saRNA and mRNA in LNPs for Vaccine Research
Posted
September 06, 2024
Identifier
NOA 2024-0164
NAICS
541714, 325414, 325412
This award supports vaccine research at the University of Alberta through specialized RNA formulation services: - Government Buyer: - University of Alberta (Canada) - OEM Highlight: - Cytiva (formerly Precision Nanosystems) technology is required for the project - Vendors: - Cytiva (formerly Precision Nanosystems) - Products/Services Requested: - Formulation of self-amplifying RNA (saRNA) into Lipid Nanoparticle (LNP) formulations using iL2V02 composition - Synthesis and characterization of three samples each of saRNA and mRNA - Unique Requirements: - Use of Cytiva's proprietary technology is essential for delivery, immunogenicity, and minimal reactogenicity of saRNA and mRNA - Sole source award due to specialized technology - Estimated Contract Value: - $322,350.43 CAD - Delivery Location: - 1400C 250 Howe Street, Vancouver, Canada
Description
The University of Alberta awarded a contract for the formulation of saRNA into Lipid Nanoparticle (LNP) formulations using the iL2V02 composition. The project includes synthesizing and characterizing three samples each of saRNA and mRNA. This work supports vaccine development research against viral infectious diseases, utilizing Cytiva's specialized technology essential for delivery, immunogenicity, and minimal reactogenicity of saRNA and mRNA. The contract is a direct award with an estimated value of $322,350.43 CAD.